Influence of IVIG on nerve excitability in multifocal motor neuropathy (MMN)
- Conditions
- Multifocal motor neuropathy (MMN). This term is familiar to all MMN patients.10034606
- Registration Number
- NL-OMON42955
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 45
1. Diagnosis of MMN according to internationally accepted criteria of the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS criteria).
2. One median nerve (left or right) with any of the following findings in the forearm segment:
(a) conduction block, defined as segmental reduction of compound muscle action potential (CMAP) area of at least 30% or signs of demyelination: conduction velocity decrease up to 38 m/s or less and/or DML 5.3 ms or more and/or increased CMAP duration prolongation in the forearm of at least 30%;
(b) motor axon loss defined as decreased CMAP amplitude of 3 mV or less;
(c) normal conduction studies.
3. Treatment with IVIG.
4. Age range will be considered between 18 and 99 years.
1. Other causes for neuropathy than MMN, including carpal tunnel syndrome (CTS).
2. Use of medication affecting peripheral nerve ion-channel currents.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To assess the change in excitability parameters induced by IVIG infusion. This<br /><br>will be achieved by comparing excitability-parameters between the time of<br /><br>maximal weakness (just before the next IVIG infusion) and the time of maximal<br /><br>clinical improvement. .</p><br>
- Secondary Outcome Measures
Name Time Method <p>To analyse the correlation between the degree of excitability changes after<br /><br>IVIG infusion, the presence of anti-GM1-antibodies and the degree of clinical<br /><br>improvement. </p><br>